Because many cancer patients have TP53+/−, we also used drug-resistant mice with Tp53 haploinsufficiency (EGFRL858R*Tp53+/−) to study the effect of p53 mutation on global gene expression during drug resistance acquisition (Fig. 8). This evidence concerns the gene TP53 and cancer.